Agios Pharmaceuticals (AGIO)
(Delayed Data from NSDQ)
$47.38 USD
+1.84 (4.04%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $47.42 +0.04 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$47.38 USD
+1.84 (4.04%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $47.42 +0.04 (0.08%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Zacks News
Agios (AGIO) Catches Eye: Stock Jumps 5.4%
by Zacks Equity Research
Agios (AGIO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Agios Pharmaceuticals (AGIO) Down 8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agios' Tibsovo Meets Endpoint in Cholangiocarcinoma Study
by Zacks Equity Research
Agios' (AGIO) Tibsovo achieves the primary goal in a late-stage development that examined it for the previously treated IDH1 mutant cholangiocarcinoma. Shares rise in after-hours trading.
Agios (AGIO) Earnings and Revenues Surpass Estimates in Q1
by Zacks Equity Research
Agios (AGIO) benefits from earnings as well as revenue beat in first-quarter 2019. However, Tibsovo sales fall sequentially, pulling the stock down.
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 8.62% and 38.64%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Agios Pharmaceuticals (AGIO) Q1 Earnings Expected to Decline
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AVEO Reports Positive Results on Leukemia Drug, Shares Up
by Zacks Equity Research
AVEO Oncology (AVEO) reports positive results from phase Ib study of ficlatuzumab in combination with cytarabine in patients with relapsed and refractory acute myeloid leukemia.
Agios (AGIO) Surges More Than 40% Year to Date: Here's Why
by Zacks Equity Research
Agios' (AGIO) first wholly owned precision medicine, Tibsovo, has been picking up the sales pace since its FDA approval last year with strong sequential growth delivered in Q4.
Agios Gains Breakthrough Therapy Status for Tibsovo Combo
by Zacks Equity Research
Agios (AGIO) receives a Breakthrough Therapy designation for Tibsovo combo to treat the newly diagnosed acute myeloid leukemia in adult patients with an IDH1 mutation.
Why Is Agios Pharmaceuticals (AGIO) Up 13.2% Since Last Earnings Report?
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agios' Tibsovo Gets FDA Priority Review in First-Line Cancer
by Zacks Equity Research
Agios' (AGIO) label expansion filing eyes an approval of Tibsovo for newly diagnosed acute myeloid leukemia patients with an IDH1 mutation. The drug also gets a priority review tag from the FDA.
Agios (AGIO) Q4 Earnings Beat, Tibsovo Sales Push Up Stock
by Zacks Equity Research
Agios' (AGIO) loss tops estimates in Q4. Its precision medicine Tibsovo receives the FDA nod and leads to significant year-over-year revenue growth.
Agios Pharmaceuticals (AGIO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 4.24% and 42.84%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Agios Pharmaceuticals (AGIO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios Pharmaceuticals (AGIO) Down 4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agios (AGIO) Q3 Earnings Beat, Tibsovo Sales Drive Stock
by Zacks Equity Research
Agios' (AGIO) loss tops estimates in Q3. Its precision medicine Tibsovo's performance in the very first quarter after approval in July leads to a significant year-over-year revenue growth.
Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 3.55% and 8.51%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Agios Pharmaceuticals (AGIO) Q3 Earnings Preview: Here's What to Look Out For
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios Rides on Tibsovo Approval Amid Reliance on Celgene
by Zacks Equity Research
Agios (AGIO) aims at commercializing its newly approved leukemia drug Tibsovo, which has great potential in the AML market. Heavy reliance on Celgene for royalties and collaboration revenues is a woe.
Agios (AGIO) Assigns Ex-Celgene Executive to CEO Position
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) names Dr. Jacqualyn Fouse as its next chief executive officer from Feb 1, 2019 onward.
Agios (AGIO) Q2 Loss Narrows, Revenues Surpass Estimates
by Zacks Equity Research
Agios (AGIO) incurs narrower-than-expected loss in Q2. Additionally, higher license and collaboration/milestone fees lead to a significant year-over-year rise in revenues.
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of 26.54% and 234.36%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Agios (AGIO) Q2 Loss Narrows, Revenue Beat Estimates
by Zacks Equity Research
Agios Pharmaceuticals (AGIO) reports narrower-than-expected loss in Q2. Higher license and collaboration milestone fees result in significant increase in year-over-year revenues.
What's in the Cards for Agios (AGIO) Stock in Q2 Earnings?
by Zacks Equity Research
On Agios' (AGIO) second-quarter 2018 conference call, investor focus is likely to be on the launch preparations of the company's newly FDA approved leukemia drug, Tibsovo.
Biotech Stock Roundup: Biogen Gains on Q2 Results, Agios Gets FDA Nod For Leukemia Drug
by Zacks Equity Research
The biotech sector is in focus as bigwig Biogen gains on better-than-expected Q2 results. Others like Gilead, Amgen and Celgene too are slated to report shortly.